Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01278
|
|||||
| Drug Name |
Zolmitriptan
|
|||||
| Synonyms |
(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one; AscoTop; AscoTop (TN); BW-311C90; Flezol; KS-5072; Zolmitriptan RapidFilm; Zolmitriptan [USAN]; Zolmitriptane; Zolmitriptanum; Zomig; Zomig (TN); Zomig Nasal Spray; Zomig ZMT; Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan; Zomig-ZMT; Zomigon; Zomigon (TN); Zomigoro (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Cluster headaches [ICD11: 8A82] | Approved | [1] | |||
| Migraine with aura [ICD11: 8A80.1] | Approved | [1] | ||||
| Migraine without aura [ICD11: 8A80.0] | Approved | [1] | ||||
| Therapeutic Class |
Antimigraine Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H21N3O2
|
|||||
| Canonical SMILES |
CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3
|
|||||
| InChI |
InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
|
|||||
| InChIKey |
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
|
|||||
| CAS Number |
CAS 139264-17-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 287.36 | Topological Polar Surface Area | 57.4 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
2.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9427
, 7847481
, 7980917
, 8187100
, 11484392
, 11488544
, 11528684
, 12014671
, 14897880
, 14922369
, 26612872
, 26680025
, 26719749
, 43118195
, 46386880
, 46386934
, 46506452
, 46530532
, 49681573
, 50730852
, 57314155
, 91011737
, 92124588
, 92308124
, 92308640
, 93166198
, 96099961
, 103346351
, 103941674
, 104179250
, 104253285
, 104321827
, 117664449
, 118855343
, 124636835
, 124757406
, 124801240
, 125164210
, 126656630
, 126667001
, 129386325
, 135017989
, 135651366
, 135692210
, 135693782
, 136974858
, 137171693
, 142742126
, 144076376
, 144205008
|
|||||
| ChEBI ID |
ChEBI:10124
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Zolmitriptan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41. | |||||
| 3 | Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.